10 Nov Verify Brand Successfully Reaches Major Milestone Toward DSCSA Compliance Effort
MINNEAPOLIS – Nov. 10, 2016 – Verify Brand is pleased to announce the recent achievement by its client, LFB USA, Inc., of a significant milestone in efforts to meet the November 2017 requirements of the U.S. Drug Supply Chain and Security Act (DSCSA). LFB USA has successfully validated its dedicated instance of Verify Brand’s cloud-based platform, the Verify Platform, which included installation, testing, protocol execution and documentation approvals.
“One of LFB USA’s main deciding factors in selecting Verify Brand was that the Verify Platform could be validated to the standards of our quality framework,” said Jim Kneece, vice president of Industrial Planning and Supply Management at LFB USA. “Verify Brand exceeded our validation expectations and clearly delivered against their service commitment of assigning proven, senior resources to ensure the highest quality delivery.”
After November 2017, the DSCSA will require prescription drug manufacturers selling product in the U.S. to serialize each sellable unit with a unique identifier and respond to FDA or customer inquiries about potentially suspicious items at the serialized level. In reaching this validation milestone, LFB USA is on track to meet its obligations under the DSCSA related to serialization and traceability of items in advance of the deadline.
Verify Brand CEO Michael Howe said, “We’re excited to reach this step in the implementation process with LFB USA because it demonstrates Verify Brand’s ability to quickly deploy DSCSA solutions to organizations in the pharmaceutical industry. From day one of Verify Brand’s partnership with LFB USA, we have been committed to meeting their regulatory compliance needs. Verify Brand is able to help all pharmaceutical manufacturers, CMOs, 3PLs and repackagers drive greater value from serialization by providing deeper supply chain process insights and extending valuable business benefits to their supply chain operations.”